The Economist @TheEconomist
The latest data shows Tofersen slows the progress of the diseases in a genetically-defined subset of patients. It highlights the benefits of using a deep understanding of the underlying biology of a disease to drive drug design https://t.co/IL455viDlI — PolitiTweet.org